Indeed, the various combinations of anti-IL-1, anti-IL-6, anti-IL-17, anti-IL-12/23 or anti-Janus kinase drugs, different doses of corticosteroids, and/or conventional immunosuppressants could be proposed as preventive and/or curative treatments in this model to preselect the best candidates for therapeutic trials in human GCA. This evidence concerns the gene IL17A and temporal arteritis.